Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 4/20 | 0.43 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.43 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.43 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | INSR | P06213 | 4/20 | 0.42 |
| ▸ | IGF1R | P08069 | 4/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.42 |
| ▸ | SMO | Q99835 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 4/20 | 0.41 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9968379 | 0.91 | SMO (0.40) | SMOMEN1KMT2A | |
| SCHEMBL9932735 | 0.90 | SMO (0.49) | SMOMEN1KMT2A | |
| SCHEMBL9968324 | 0.87 | MEN1 (0.44) | SMOMEN1KMT2A | |
| SCHEMBL9931667 | 0.86 | SMO (0.40) | SMOMEN1KMT2A | |
| SCHEMBL12841515 | 0.86 | MKNK1 (0.46) | SMOHTR3AMEN1KMT2A | |
| SCHEMBL9932138 | 0.86 | SMO (0.54) | SMOMEN1KMT2A | |
| SCHEMBL9932494 | 0.85 | SMO (0.37) | SMOMEN1KMT2A | |
| SCHEMBL9932496 | 0.85 | DGAT1 (0.41) | SMOMEN1KMT2A | |
| SCHEMBL9968360 | 0.85 | SMO (0.38) | SMOMEN1KMT2A | |
| SCHEMBL9931952 | 0.85 | OPRM1 (0.40) | SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027249-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | ACVR1 476/4885BMPR1B 172/4885BMPR1A 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.